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Abstract: Patients undergoing major orthopedic surgery, total hip arthroplasty (THA) and total 
knee arthroplasty (TKA) are at high risk of venous thromboembolism, manifesting as deep vein 
thrombosis or pulmonary embolism. The recommended pharmacologic treatment options for 
thromboprophylaxis after major orthopedic surgery include the vitamin K   antagonists (VKAs 
eg, warfarin), low molecular weight heparins (LMWHs; eg, enoxaparin) and the synthetic 
pentasaccharide fondaparinux. Most clinics use some kind of thromboprophylaxis routinely. 
However, due to the frequent need for coagulation monitoring (VKAs) and subcutaneous 
  injections (LMWHs and fondaparinux) barriers exist to prescribing prophylaxis after discharge 
from hospital. Targeting specific components of the coagulation cascade has yielded several 
new antithrombotic agents for use as thromboprophylaxis after THA or TKA. Two of these, 
dabigatran etexilate and rivaroxaban, have already reached the markets in the European Union 
member states and Canada. Both are administered by the oral route, once-daily fixed dose 
and without the need to monitor the anticoagulant effect. Whether these new drugs facilitate 
  guideline adherence, particularly in the outpatient settings and thereby improve the overall 
clinical outcomes remains to be shown.
Keywords: dabigatran etexilate, rivaroxaban, thromboprophylaxis, total joint arthroplasty, 
venous thromboembolism
Introduction
Patients undergoing major orthopedic surgery, total hip arthroplasty (THA) and 
total knee arthroplasty (TKA) are at high risk of venous thromboembolism (VTE), 
  manifesting as deep vein thrombosis (DVT) or pulmonary embolism (PE).1 Without 
prophylaxis, 41%–85% of patients may develop DVT (detected by venography), 
0.9%–28% may develop PE, and 0.1%–7.5% may suffer a fatal PE.1 Traditional 
  pharmacologic treatment options for thromboprophylaxis after major orthopedic   surgery 
include the vitamin K antagonists (VKAs; eg, warfarin), unfractionated heparin (UFH), 
low molecular weight heparins (LMWHs; eg, enoxaparin) and the synthetic pentasac-
charide fondaparinux. Adjusted-dose VKA, LMWH or fondaparinux are recommended 
for patients undergoing THA with a duration of at least 10 days and extended for up to 
35 days (grade 1A recommendation). For patients undergoing TKA the same regimens 
are recommended with a duration of at least 10 days (grade 1A recommendation) and 
with extension for up to 35 days (grade 2B recommendation).1 Most clinics use some 
kind of thromboprophylaxis routinely. However, due to frequent need for coagulation 
monitoring (VKAs) and subcutaneous injections (LMWHs and fondaparinux) barriers 
exist to prescribing prophylaxis after discharge from hospital.2Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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Dovepress
124
Borris
In the USA the annual number of primary THAs and TKAs 
in 2004 was around 700,000 a number which is expected to 
increase in the future.3 By extrapolation, based on the size 
of the population and anticipating an equal need for these 
operations in the European Union (EU) the annual number of 
primary arthroplasties is at least 1.5 million performed in EU 
and USA; this makes the prophylaxis market very attractive 
for drug developers. Intensive research has therefore been 
carried out during the last 10 years with the focus being on 
finding new antithrombotic compounds. The dominating 
research philosophy has favored new compounds that can be 
administered orally at a fixed dose, without a need for coagula-
tion monitoring, and with an inhibitory action on the activated 
Factor X (FXa) or on thrombin, Factor IIa (FIIa).
Pathogenesis of vTe
The pathogenesis of VTE was first proposed by the famous 
German scientist Virchow, and is referred to as Virchow’s 
triad.4 According to his triad three independent factors are 
involved: a) Vascular stasis; b) Endothelial wall damage; 
and c) Hypercoagulability.
In major orthopedic surgery, damage to the bone marrow 
which is rich in tissue factor (TF), impaction of bone cement, 
and stasis during and after the surgical procedure, triggers a 
substantial local and systemic thrombin generation and activity, 
due to TF release, that predisposes to thrombus formation at the 
site of surgery.5 The coagulation cascade is shown in Figure 1. 
In conjunction with Factor VIIa, TF activates Factor Xa (FXa) 
directly (the extrinsic pathway); or via propagation of the tenase 
complex (Factor VIIIa + Factor IXa) on an activated platelet 
membrane (the intrinsic   pathway).6 The prothrombinase com-
plex is then formed on the platelet surface and incorporation of 
FXa into this complex increases the rate of thrombin genera-
tion. The thrombin-generating efficacy of the prothrombinase 
complex is much more pronounced than that of free FXa.7–9 
and it has been estimated that one molecule of FXa catalyzes 
the formation of ∼1000 thrombin molecules.6 Thus, FXa is 
the pivotal point in the coagulation cascade because it can be 
activated both by the extrinsic and intrinsic pathways; further-
more the only function of FXa in the coagulation process is to 
promote coagulation and to amplify the events.
Indirect and direct FXa inhibition
UFH and LMWH are indirect FXa inhibitors because they 
inhibit FXa by potentiation of the natural inhibitory action 
of antithrombin (AT) that is an endogenous plasma protein 
(Figure 1). In addition, UFH also has an inhibitory action on 
several other coagulation factors the most important of which 
is FIIa, thrombin. LMWH has a more specific inhibitory action 
on FXa with some differences between the various compounds. 
Fondaparinux is a synthetic pentasaccharide with the same 
mode of action as UFH and LMWH, although in contrast to 
those it acts solely by the AT-mediated inhibition of FXa.10 
Direct FXa inhibitors do not need AT to inhibit FXa, because 
Figure 1. The coagulation cascade with indication of the mechanism of action of indirect and direct Factor Xa inhibitors and direct thrombin inhibitors
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they are able to bind directly to the active site of FXa and 
thereby preventing interaction with its substrates. As a conse-
quence the direct FXa inhibitors are able to inhibit both free FXa 
and bound FXa in the prothrombinase   complex11 (Figure 1).
Emerging antithrombotic agents  
for the prevention of VTE  
after THA and TKA
Targeting specific components of the coagulation cascade has 
yielded several promising new antithrombotic agents with the 
potential for use as thromboprophylaxis after THA or TKA. 
The main features of the agents that are in development are 
summarized in Table 1.
Dabigatran etexilate
Dabigatran etexilate (Boehringer Ingelheim, International 
GmbH, Germany) is an oral, once daily (od), direct throm-
bin inhibitor. It has a rapid onset of action and an estimated 
half-life of 8–10 hours and 14–17 hours with single- and 
multiple-dose administration, respectively. Due to its predict-
able pharmacokinetics (PK) and pharmacodynamics (PD), it 
is administered at a fixed dose without the need for routine 
coagulation monitoring.12 In patients ,75 years of age and 
having normal kidney function the drug is started 1–4 hours 
after THA with 110 mg and continued with 220 mg od for 
28–35 days, in other patients the dosage should be reduced to 
a starting dose of 75 mg and a continuation dose of 150 mg.13 
Interactions with other drugs are shown in Table 1.
Clinical documentation
The phase III RE-NOVATE trial investigated dabigatran 
etexilate versus enoxaparin for the prevention of VTE after 
THA in 3,494 patients.14 Patients were randomized to receive 
oral dabigatran etexilate 150 mg or 220 mg od, starting with 
a half-dose 1–4 hours after surgery, or subcutaneous enox-
aparin 40 mg od, starting the evening before surgery, for 
28–35 days. The primary efficacy outcome of this study was 
the zero incidence of VTE and all causes of mortality during 
treatment. The primary safety outcome was the occurrence of 
bleeding events during treatment. Major bleeding events were 
defined as follows: clinically overt bleeding associated with a 
$2 g/dL fall in hemoglobin; clinically overt bleeding leading 
to a transfusion of $2 units of packed cells or whole blood; 
fatal, retroperitoneal, intracranial, intraocular, or intraspinal 
bleeding; or bleeding warranting treatment cessation or 
leading to re-operation. Both doses of dabigatran etexilate 
(150 mg and 220 mg) were noninferior to enoxaparin 40 mg 
od (8.6% and 6.0%, respectively, versus 6.7%; P , 0.0001 
for noninferiority versus enoxaparin) for the primary efficacy 
outcome. The incidence of major VTE (proximal DVT and 
PE) was also similar between both doses of dabigatran and 
enoxaparin (4.3% and 3.1%, respectively, versus 3.9%). 
Symptomatic DVT occurred in 0.8% (150 mg) and 0.5% 
(220 mg) of patients receiving dabigatran, and in 0.1% of 
those receiving enoxaparin. The frequency of symptomatic 
PE was 0.1%, 0.4%, and 0.3% for dabigatran 150 mg, 
220 mg, and enoxaparin, respectively. Major bleeding 
occurred in 1.3% (150 mg) and 2.0% (220 mg) of patients 
receiving dabigatran etexilate and in 1.8% of those receiving 
enoxaparin. The incidence of clinically relevant nonmajor 
bleeding was 4.7% and 4.2% for patients receiving dabigatran 
150 mg and 220 mg, respectively, compared with 3.5% for 
those who received enoxaparin.
Two phase III studies (RE-MODEL and RE-MOBILIZE) 
for VTE prevention after TKR have also been published. 
The RE-MODEL study, showed that dabigatran was non-
inferior to enoxaparin 40 mg od for both safety and efficacy;15 
however, in the RE-MOBILIZE study both doses of dab-
igatran (110 mg and 220 mg od) were inferior to the North 
American regimen of enoxaparin (30 mg twice daily), 34% 
and 31%, respectively, versus 25%.16 Based on the results of 
these phase III studies, dabigatran etexilate was approved in 
2008 for the prevention of VTE after THA or TKA in all 27 
European Union member states and Canada.
Rivaroxaban
Rivaroxaban (Bayer Schering Pharma AG, Germany; Johnson 
& Johnson Pharmaceutical Research and Development, NJ, 
USA) is an oral od direct FXa inhibitor.17 It also inhibits pro-
thrombinase activity, as well as free and clot-associated FXa 
activity.18,19 It has a half-life of 7–11 hours.19,20 Rivaroxaban 
is well tolerated, with a rapid onset of action, reaching peak 
plasma concentrations within 2 to 4 hours. It has predictable 
PK and PD, thus can be given at a fixed dose with no need 
for routine coagulation monitoring.19 Additionally, it has no 
known food–drug or drug–drug interactions in the interaction 
studies published so far.20–22 However, a number of interac-
tions with other drugs are shown in Table 1. Rivaroxaban at 
a dose of 10 mg is started 6 to 10 hours after surgery and 
continued od for a total of 5 weeks after THA and 2 weeks 
after TKA.23
Clinical documentation
Based on the results from phase II studies, a dose of 10 mg od 
was regarded as an optimal dose in terms of efficacy and 
safety, and was chosen for the phase III studies.24Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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The RECORD program consists of 4 clinical prophylaxis 
studies presented in Table 2. All studies were prospective, 
double blind, randomized studies comparing the antithrom-
botic efficacy and safety of rivaroxaban 10 mg given orally 
od and enoxaparin 40 mg once daily or 30 mg twice daily 
in patients undergoing THA or TKA.25–28 RECORD 1 and 
RECORD 2 were performed in THA patients and 40 mg once 
daily of enoxaparin was used for comparison in both   studies. 
In RECORD 1 both prophylactic regimens were given for 
a total duration of 35 ± 4 days (long-term). In RECORD 2 
only rivaroxaban was given long-term when compared with 
enoxaparin which was only given for 10–14 days (  short-term) 
(Table 3), because it is not universally accepted to use long-
term prophylaxis after THA in spite of the   recommendation 
in the ACCP guidelines.1 RECORD 3 and RECORD 4 were 
performed in TKA patients with a treatment duration in both 
arms of 10–14 days. In RECORD 3 10 mg of rivaroxaban 
once daily, started 6–8 hours after surgery, was compared with 
40 mg of enoxaparin, started in the evening before surgery. 
In RECORD 4 enoxaparin 30 mg twice daily started 12–24 h 
after surgery was used in the comparator arm (Table 2). The 
efficacy results of the RECORD studies are presented in 
Tables 3 and 4. In all four studies rivaroxaban was significantly 
more effective in reducing the primary efficacy endpoint, 
the composite of the incidence of any DVT (proximal and/
or distal), nonfatal symptomatic, objectively confirmed PE 
and all cause deaths. In RECORD 1–3 also major VTE, the 
composite of proximal DVT, PE and VTE-related death, was 
  significantly reduced compared with enoxaparin (Table 3). 
In the RECORD 2 and RECORD 3 studies rivaroxaban also 
significantly reduced the incidence of symptomatic VTE 
events compared with   enoxaparin (Table 4), which are impor-
tant observations from a clinical point of view. The primary 
safety outcome was major bleeding – defined as follows: fatal 
bleeding;   bleeding into a critical organ (eg, retroperitoneal, 
Table 2 Design of the double blind, randomized phase iii prophylaxis 
studies in major joint arthroplasty surgery
Study title Operation Doses (mg) Duration of 
prophylaxis 
(days)
riva. enox. riva. enox.
ReCORD 125 THA 10 oda 40 odb 35 ± 4 35 ± 4
ReCORD 226 THA 10 oda 40 odb 35 ± 4 10–14
ReCORD 327 TKA 10 oda 40 odb 10–14 10–14
ReCORD 428 TKA 10 oda 30 bidc 10–14 10–14
Notes: aStarted 6–8 h after surgery (tablets); bStarted on the evening before surgery 
(injected subcutaneously); cStarted 12–24 h after surgery (injected subcutaneously).
Abbreviations: THA, total hip arthroplasty; TKA, total knee arthroplasty; Riva, 
rivaroxaban; Enox, enoxaparin; OD, once daily; Bid, twice daily.
Table 3 Efficacy results of the RECORD studies
Study title Rando- 
mized 
N
Primary 
efficacy 
endpointa %
Relative 
risk 
reduction 
% 
P-value 
for 
difference
riva. enox.
ReCORD 125 4541 1.1 3.7 70 ,0.001
ReCORD 226  2509 2.0 9.3 79 ,0.001
ReCORD 327  2531 9.6 18.9 49 ,0.001
ReCORD 428  3148 6.9 10.1 31 0.012
Note: aPrimary efficacy endpoint was the composite of the incidence of any deep 
vein thrombosis (DVT) (proximal and/or distal), nonfatal symptomatic, objectively 
confirmed pulmonary embolism (PE) and all cause deaths.
Abbreviations: Riva, rivaroxaban; Enox, enoxaparin.
intracranial, intraocular, or intraspinal); bleeding requiring 
re-operation; and clinically overt extra-surgical-site bleeding 
associated with a fall in hemoglobin $2 g/dL or requiring 
an infusion of $2 units of blood or packed cells. Clinically 
relevant nonmajor   bleeding,   hemorrhagic wound complica-
tions, and other nonmajor bleeding events were among the 
other safety outcomes. Table 5 shows the incidence of major 
bleeding in the RECORD   studies. There were no important 
differences between the groups. There were not any observed 
differences in action on the liver function when rivaroxaban 
was used for long-term prophylaxis in the RECORD 1 and 
RECORD 2 studies compared with short-term prophylaxis 
with rivaroxaban.
Some authors have claimed that the definition of major 
bleeding used in the RECORD program did not include surgi-
cal site bleedings,29,30 however, this is only partially   correct 
as the clinically most important surgical site bleedings: 
fatal bleeding or reoperation due to bleeding were covered 
by the definition. Hemorrhagic wound complications and 
wound infections were reported separately. This has led to 
speculations about underestimation of the major bleeding 
rates in the RECORD studies.30,31 However, when major 
bleedings, nonmajor clinically relevant bleedings and surgical 
site bleedings were combined across all RECORD studies 
Table 4 Symptomatic vTe events of the ReCORD studies
Study title Symptomatic VTE eventsa    
during treatment % 
P-value for   
difference
riva. enox.
ReCORD 126 0.3 0.5 0.22
ReCORD 227 0.2 1.2 0.004
ReCORD 328 0.7 2.0 0.005
ReCORD 429 0.7 1.2 0.19
Notes: aSymptomatic venous thromboembolism (VTE) included any symptomatic 
DVT (proximal or distal) and non-fatal or fatal PE in patients in the safety population 
who had undergone surgery.
Abbreviations: Riva, rivaroxaban; Enox, enoxaparin.Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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only a trend towards a lower bleeding rate with enoxaparin 
compared with rivaroxaban was seen (1.37% versus 1.80%; 
P = 0.063).31 The belief that bleeding rates obtained in one 
clinical study can be directly compared with bleeding rates 
in another study, as long as the same definitions are used, is a 
common misapprehension. Not just the use of anticoagulants 
but also a variety of other study-specific factors influence 
the final bleeding outcomes of a clinical study in terms of 
surgical approach, the skill of the participating surgeons, the 
type of implant used, the use of drains, perioperative use of 
antifibrinolytics, country-specific guidelines for the use of 
blood products, the availability of blood for   transfusion and 
the surgeon’s threshold for reporting a bleeding complica-
tion. Direct comparison of bleeding rates between various 
treatment options reported in different clinical, multi-center, 
studies conducted in different countries is therefore mis-
leading. The only recommendable approach to assess the 
bleeding risk with an antithrombotic drug regimen is to 
compare the rates of bleeding in the treatment arms within 
the same study, on the condition that a double-blind design 
is used and all bleedings are adjudicated by an independent, 
blinded committee.
Apixaban
Apixaban (Bristol-Myers Squibb, New York, NY, USA) 
is an oral, direct FXa inhibitor and has been evaluated 
in a phase III study for the prevention of VTE after TKA 
(ADVANCE-1). Results from this study indicated that apixa-
ban (2.5 mg twice daily [bid]) did not meet the pre-specified 
criteria for noninferiority compared with enoxaparin (30 mg 
bid) with respect to the primary efficacy endpoint; however, 
rates of major bleeding and nonmajor clinically relevant 
bleedings were significantly reduced with apixaban.32 The 
ADVANCE-2 study compared apixaban (2.5 mg bid) with 
enoxaparin (40 mg od) in patients undergoing TKA.33 The 
incidence of the primary endpoint was 15.1% and 24.4% 
for the apixaban and enoxaparin groups, respectively 
(P , 0.0001). Major VTE (a composite of proximal DVT, 
symptomatic nonfatal PE, and VTE-related death) occurred 
less frequently in the apixaban group (1.1%) compared with 
the enoxaparin group (2.2%; P = 0.019). Symptomatic VTE 
events and VTE related deaths occurred at an equal rate of 
0.46% in the two groups. The major bleeding rate and the 
rate of clinically relevant nonmajor bleeding did not differ 
between the groups although there was a trend towards a 
lower incidence with apixaban. Apixaban 2.5 mg bid has 
also been compared with enoxaparin (40 mg od) in patients 
undergoing THA in the ADVANCE-3 study which has been 
completed but is not yet reported.
Other anticoagulants under 
development
As shown in Table 1 several other oral, direct FXa inhibitors 
are in clinical development, including YM150, betrixaban 
and DU-176b36,38 (now called edoxaban). Their comparative 
efficacy and potential place in thromboprophylaxis after THA 
or TKA remains to be evaluated.
A new parenterally administered 
compound under way
A new hemisynthetic ultra-low-molecular-weight heparin 
(AVE5026) for the prevention of VTE after THA and TKA is 
also undergoing clinical development.38 The drug has a high 
anti-FXa activity and residual anti-FIIa activity. In a phase 
II dose ranging study patients undergoing TKA were treated 
with the following once-daily doses of AVE5026 injected 
subcutaneously: 5, 10, 20, 40, or 60 mg or enoxaparin 40 mg 
once-daily as a comparator. There was a significant dose 
response for prevention of VTE across the different doses 
ranging from 5.3% to 44.1% compared with 35.8% in the 
enoxaparin group. The VTE rate was high, but when compared 
with other contemporary TKA studies it was within the same 
range.38 There was also a significant dose response in terms of 
major bleeding and any bleeding. Based on this study it was 
decided that a dose of 20 mg of AVE5026 was to be used in 
a large phase III program which is ongoing.
Patient considerations
Whether oral drug administration is more accepted by 
patients than administration by injection is a contention 
that is difficult to disprove, although it lacks positive sup-
porting evidence. First of all this is only a real problem 
after discharge because nurses are readily available as long 
as the patients are in hospital. Bergqvist and Jonsson in 
1999 reported that the cost-effectiveness of enoxaparin was 
reduced when the injections were to be administered by a 
Table 5 Safety results of the ReCORD studies
Study title  Major bleedinga % P-value for   
difference riva. enox.                 
ReCORD 126 0.3 0.1 0.18
ReCORD 227 0.1 0.1 NS
ReCORD 328 0.6 0.5 0.77
ReCORD 429 0.7 0.3 0.11
Notes: aprimary safety endpoint was the incidence of major bleeding (according to 
preset criteria) starting after the first postoperative dose of study drug, but no later 
than 2 days after the last dose of study drug.
Abbreviations: Riva, rivaroxaban; Enox, enoxaparin.Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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home nurse, because patients were not able or willing to 
self-inject at home after hospital discharge.39 Poor compli-
ance with oral ximelagatran (no longer available due to liver 
toxicity) has been reported previously in patients undergo-
ing TKA with only 90%   adherence to an 8-day regimen.40 
However, it is not possible to solve the dispute regarding 
the advantages of oral versus subcutaneous administration 
of anticoagulants based on existing data because patient 
behavior in a controlled   clinical study cannot be compared 
with the real-life situation. XAMOS (Xa inhibition in the 
prophylaxis of post-surgical venous thromboembolism 
after elective major orthopedic surgery of hip or knee) is an 
ongoing post-marketing,   noninterventional study comparing 
the efficacy and safety of rivaroxaban with   various exist-
ing prophylactic regimens. The study is planned to involve 
15,000 patients undergoing THA or TKA worldwide and is 
designed to evaluate how the new drug functions in a real-
life setting including compliance issues.
Another aspect has been whether nausea and vomiting 
can negatively influence oral drug intake, which is at least a 
  theoretical benefit to the injectable route, or whether the oral 
drug intake in the early postoperative period could cause these 
symptoms. This was the reason why the first oral antithrom-
botic regimen on the market, ximelagatran, was initiated by 
subcutaneous injection of melagatran for the first days after 
the operation followed by oral intake.42 There is not many 
data on compliance with oral antithrombotics; however, low 
incidences of nausea and vomiting were reported to be high 
in one of the phase II studies with rivaroxaban when the drug 
was administrated early postoperatively.42
The lack of an antidote for many of these new com-
pounds has been criticized and noted as a potential risk.43 
The relatively short half-life which enables a quick reversal 
of the anticoagulant effect after treatment cessation and a 
possibility to administer recombinant active factor VII or 
activated prothrombin complex concentrate is suggested 
in selected cases has been advised having administered 
rivaroxaban.43
Finally, an issue with implications to patients undergoing 
orthopedic procedures is the concern regarding the safety of 
new anticoagulants when used in combination with neuraxial 
anesthesia/analgesia. The basic recommendation is to wait 
two half-lives after intake of an anticoagulant drug before 
a central neuraxial block is performed and in the case of 
indwelling catheters these should be removed with the same 
time interval after intake.44 Because most of the new anti-
thrombotic regimens are designed to start postoperatively this 
precaution is not a problem, except when epidural analgesia 
is used after an operation as this is still common practice in 
some countries.
Conclusion
With the convenience of oral, fixed dosing and no need for 
routine coagulation monitoring, the introduction of new 
anticoagulants into clinical practice may facilitate guideline 
adherence, particularly in the outpatient settings, in patients 
undergoing THA or TKA, and have the potential to improve 
overall clinical outcomes. In case all compounds that are 
currently in development finally reach the market it will be 
good news for both patients and health services as it will 
inevitably result in lower clinical costs. The situation was 
seen with LMWH in the 1990’s where heavy competition 
between the various drug companies reduced the selling 
prices dramatically.
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